What the trial was testing
The trial enrolled 16 patients with celiac disease. The study was sponsored by Takeda and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
Researchers followed patients through treatment and into recovery, tracking the outcomes that mattered most for the disease being studied.
What the results showed
Interleukin-2 was the earliest and most sensitive marker of gluten exposure in people with celiac disease.
Gastroenterology · 2021 · NCT03409796
These findings — that this blood marker detected gluten exposure faster than biopsies or other tests — were published in the Gastroenterology and represent the headline result of the study.
Researchers tracked outcomes across 16 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with celiac disease, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This was an early-stage study designed to improve how researchers test celiac disease treatments, not to test a new treatment itself. The findings may help future studies use blood tests instead of biopsies to measure disease activity. If you have celiac disease, continue following a strict gluten-free diet and talk to your doctor about any questions regarding diagnosis or monitoring.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open celiac disease trials
Gluten Technology and Education for Celiac Health
The investigators propose to plan for a multi-center randomized controlled trial (M-RCT) to test the effectiveness of novel gluten detection technologies as an adjunct to telemedicine to manage celiac disease in newly diagnosed adults. If successful, the proposed intervention will improve mucosal recovery, promote a shift in current practice of celiac disease management toward long-term monitoring, and represent a significant step toward reducing the severe physical and psychological consequences of celiac disease.
Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet